Clinical Research Directory
Browse clinical research sites, groups, and studies.
Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City
Sponsor: Zhongshan People's Hospital, Guangdong, China
Summary
The study includes two cohorts: (1) a serological screening cohort; (2) a serological and EBV DNA screening cohort. All participants will be tested for EBNA1-IgA, VCA-IgA, BNLF2b total antibodies (P85-Ab), with additional plasma EBV DNA testing in the latter cohort. Screening positive participants will be followed up annually. All subjects will also be followed by record linkage to Cancer Register and Population Register.
Official title: Searching for Early Detection Biomarkers of Nasopharyngeal Carcinoma in Zhongshan City
Key Details
Gender
All
Age Range
30 Years - 69 Years
Study Type
OBSERVATIONAL
Enrollment
40000
Start Date
2020-04-01
Completion Date
2030-12-31
Last Updated
2026-09-29
Healthy Volunteers
Yes
Conditions
Interventions
Blood and saliva
Collect blood and saliva samples from participants
P85-Ab, EBNA1-IgA, VCA-IgA
Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants.
Consecutive EBV DNA testing
All participants undergo baseline EBV DNA testing. Those with positive results are invited for repeat testing approximately 4 weeks later. Consecutive positivity is defined as positive results at both tests.
Fiberoptic endoscopy and biopsy
Screening participants with high risk or P85-Ab positive will refer to fiberoptic endoscopy and biospy
Fiberoptic endoscopy and biopsy
Screening participants with high risk or P85-Ab positive or consecutive EBV DNA positive will refer to fiberoptic endoscopy and biospy
Locations (2)
Zhongshan People's Hospital
Zhongshan, Guangdong, China
Wuzhou Red Cross Hospital
Wuzhou, Guangxi, China